Image of a heart Novartis announces Entresto

Novartis announces Entresto ™ ▼ can be initiated with safety and tolerability in patients...

Novartis presented new data from the TRANSITION study at The British Society of Heart Failure (BSH) 21st Annual Autumn Meeting (29-30 November) in London....
Orion has been responsible for selling and marketing Stalevo in the Nordic and Baltic countries, Germany, Poland, the United Kingdom and Ireland. Under the concluded agreement, the sales and marketing rights for Stalevo will transfer back to Orion in another 18 EU countries and also some European countries outside of the EU.

Orion acquires sales & distribution rights for certain EC countries for Stalevo

Orion Corporation and Novartis Pharma AG have agreed that Novartis will return the sales and distribution rights in certain European countries for Parkinson's disease...
GSK has reached an agreement to acquire oncology-focused biopharma company TESARO

GSK reaches agreement to acquire TESARO

GlaxoSmithKline plc (GSK) and TESARO Inc have entered into a definitive agreement within which GSK will acquire TESARO, an oncology-focused company based in Waltham,...
Birmingham health researchers, with industry partners, have been awarded £1.1 million to investigate patients’ experience of cell and gene therapies.

Birmingham team to lead research into patient experience of cell therapies

Birmingham health researchers, along with industry partners, have been awarded £1.1 million by UK Research & Innovation (UKRI)’s Innovate UK, to investigate patients’ experience...
Robert M. Davis will present to Citi's annual 2018 Global Healthcare Conference

Merck to present at Citi 2018 Global Healthcare Conference

Merck (MSD outside the United States and Canada), has announced that Robert M. Davis, chief financial offer and executive vice president, Merck Global Services,...

UK pharma pressing ahead with M&As in 2019

The UK pharmaceutical industry is pressing ahead with M&A activity and is geared to weather any disruption due to Brexit, according to the results...
Wider choices of contraception needed to reduce clinic overload and costs.

Contraceptive services cuts lead to call for wider choice

Nurses are "ideally placed" to advise on wider choices of contraception to reduce clinic overload and costs, according to a senior contraception and sexual...
Orion has been responsible for selling and marketing Stalevo in the Nordic and Baltic countries, Germany, Poland, the United Kingdom and Ireland. Under the concluded agreement, the sales and marketing rights for Stalevo will transfer back to Orion in another 18 EU countries and also some European countries outside of the EU.

Early stage skin cancer immunotherapy Opdivo approved in England

Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the reimbursement...
NICE recommends Stivarga

NICE recommends Stivarga ® for advanced unresectable HCC

NICE recommends Stivarga® (regorafenib) for treatment of adult patients with advanced unresectable hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Bayer has announced that...
European Commission approval for KALYDECO

Vertex announces European Commission approval for KALYDECO®

Vertex announces European Commission approval for KALYDECO ® (ivacaftor) to treat patients with cystic fibrosis aged 12 to <24 months with certain mutations in the...

Latest articles

Maxwellia makes two new appointments

Maxwellia expand their team with two new appointments

Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator. 
BMS & Boston Medical Center enter collaboration

BMS & Boston Medical Center announce research collaboration

BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
Syringe with liquid

EC approves KEYTRUDA® as adjuvant therapy

MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...